Innovative Treatment ApproachThe pivot into inflammatory bowel disease is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.
Investor InterestKey Phase 1 milestones for SL-325 are expected to spur investor interest, marking the first clinical data following the company's strategic pivot.
Preclinical DataEncouraging IND-enabling data for SL-325 indicates a clean safety profile and favorable dosing, which aligns with approved therapies.